Computational discovery of curcumin 4′-O-β-D-gentiobioside as a dual anti-virulence and anti-cancer agent
Open Access
- 17 July 2026
- journal article
- research article
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
Abstract
Objective (s) Despite the established epidemiological synergy between Porphyromonas gingivalis-induced periodontitis and oral squamous cell carcinoma (OSCC), a critical gap remains in developing single-agent therapeutics that simultaneously neutralize bacterial virulence and suppress host oncogenic signaling. This study aimed to comprehensively evaluate Curcumin 4'-O-β-D-gentiobioside (COG) as a novel, dual-pathway phytochemical intervention targeting the keystone virulence factor RgpB while concurrently disrupting OSCC progression networks. Materials and methods A multi-modal computational approach was used, including network pharmacology, molecular docking, molecular dynamics simulations, and ADMET profiling. Anti-aging activity was predicted through pharmacological activity modeling. Results Network pharmacology identified Curcumin 4'-O-β-D-gentiobioside (COG; PubChem CID: 46926100) targeting hub genes (TNF, IL6, EGFR, AKT1), enriching immune regulation, apoptosis, and oxidative stress pathways (FDR < 0.05). Docking revealed strong binding to RgpB (XP GScore: − 9.867 kcal/mol), supported by hydrogen bonds and π-stacking. Molecular dynamics confirmed stability (RMSD: 1.0–1.5 Å; ΔG = − 14 kcal/mol). COG downregulated pro-inflammatory (CXCL10, MAPK8) and oncogenic (MDM2, BCL2L1) mediators, while enhancing ER stress response (KDELC1, ATF4). ADMET analysis predicted high absorption, negligible neurotoxicity, and no hepatotoxicity/genotoxicity. Predicted anti-aging activities included senolytic, antioxidant, and NF-κB inhibition. Conclusion(s) These results position COG as a promising dual-agent that concurrently neutralizes RgpB virulence, disrupts chronic inflammation, and suppresses OSCC progression, addressing a critical unmet need in oral disease therapeutics. These findings warrant in vivo validation for translation into oral disease therapeutics. Graphical AbstractKeywords
This publication has 149 references indexed in Scilit:
- Berberine: A novel therapeutic strategy for cancerIUBMB Life, 2020
- Investigating Protein–Peptide Interactions Using the Schrödinger Computational Suite2017
- The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence AnalysesCurrent Protocols in Bioinformatics, 2016
- Biological Network Exploration with Cytoscape 3Current Protocols in Bioinformatics, 2014
- Wogonin suppresses human alveolar adenocarcinoma cell A549 migration in inflammatory microenvironment by modulating the IL‐6/STAT3 signaling pathwayMolecular Carcinogenesis, 2014
- Breaking bad: Manipulation of the host response by Porphyromonas gingivalisEuropean Journal of Immunology, 2013
- Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichmentsJournal of Computer-Aided Molecular Design, 2013
- Exploring Biological Networks with Cytoscape SoftwareCurrent Protocols in Bioinformatics, 2008
- Galanin Increases Cytoplasmic Calcium in Insulin-Producing RINm5F Cells by Activating Phospholipase C: Volume221,Number 1 (1996), pages 89–94Biochemical and Biophysical Research Communications, 1996
- Phenotypic characterization, karyotype analysis and in vitro tamoxifen sensitivity of new ER‐negative vulvar carcinoma cell lines, UM‐SCV‐1A and UM‐SCV‐1BInternational Journal of Cancer, 1990